CJC-1295 + Ipamorelin: the pulse stack, honestly assessed.

Why this pairing keeps coming up

Search volume for CJC-1295 + Ipamorelin doesn’t fall. It rose through the 2010s as testosterone clinics broadened into peptide practice, plateaued during the regulatory churn, and is now climbing again on the back of an unexpected driver: people coming off GLP-1 drugs and looking for a way to put back the lean mass and facial volume the GLP-1 took with the fat.

The reason this pair specifically endures — rather than dozens of other plausible pairings in the growth hormone (GH) space — is that it solves a very specific problem in a very specific way. GH is a pulse hormone. The body releases it in bursts roughly every three hours, with the largest burst in early sleep. CJC-1295 and Ipamorelin each push a different switch in that pulse machinery. Combined, they raise the amplitude of a pattern the body already runs. They don’t replace it.

That distinction matters more than almost anything else in this article, so we’ll come back to it. First — the receptor story.

Mechanism: two levers of one pulse

Two specific cell types in the anterior pituitary release growth hormone: the somatotrophs. They listen to two upstream signals from the hypothalamus. One signal tells them to make more GH and get it ready to release. The other tells them when to release it. CJC-1295 is a synthetic analog of the first signal. Ipamorelin mimics the second.

CJC-1295 (no DAC) is a tetrasubstituted analog of growth hormone-releasing hormone (GHRH), the natural hypothalamic signal that loads the pituitary’s readily-releasable pool of GH. It binds the GHRH receptor on somatotrophs and activates the Gs/cAMP pathway, which has the practical effect of telling the cell to top up the GH it has ready to release.

Ipamorelin is a pentapeptide ghrelin-receptor agonist. It binds GHS-R1a, the same receptor that endogenous ghrelin activates from the stomach. Activation triggers the Gq/phospholipase C pathway, which raises intracellular calcium and causes the somatotroph to actually exocytose the GH that’s waiting. It also, importantly, suppresses somatostatin tone at the hypothalamus — meaning it removes the brake while it presses the accelerator ².

The pairing isn’t additive. It’s synergistic. GHRH-analog co-administration with a ghrelin-receptor agonist produces a larger GH release than the sum of each compound’s independent pulse, because each is simultaneously raising the readiness state and pulling the brake the other can’t reach. That synergy is well-established for GHRH-plus-ghrelin pairings broadly in the endocrinology literature, even though the specific CJC-1295 + Ipamorelin combination has not been formally studied in a published RCT.

“CJC-1295 stocks the warehouse. Ipamorelin opens the loading dock. Used together, they amplify the body’s existing rhythm. Used as a depot, you stop amplifying the rhythm and start replacing it.”

Why the no-DAC version specifically

The original CJC-1295 patent included a feature called the Drug Affinity Complex (DAC) — a chemical handle that binds the molecule to circulating albumin and extends its half-life to roughly 5.8–8.1 days. The 2006 Teichman JCEM Phase 1 paper documented that DAC-CJC-1295 raises mean GH 2–10-fold for six days or more and IGF-1 1.5–3-fold for nine to eleven days after a single subcutaneous dose ¹. Impressive numbers. And exactly the wrong shape.

An eight-day half-life means GH is no longer a pulse. It’s a smear — tonically elevated GH and IGF-1 for the better part of two weeks per dose. That looks like exogenous HGH replacement, not endogenous augmentation. Sustained tonic stimulation of somatotrophs has known consequences: receptor downregulation, suppression of natural pulsatile output, and loss of the somatostatin feedback rhythm. None of which the people seeking out this pairing usually want.

Removing DAC drops the half-life to about thirty minutes. That’s short enough to overlay a near-physiologic pulse pattern when dosed once or twice a day — tall, sharp, and brief, the way the body does it. Ipamorelin’s roughly two-hour half-life behaves the same way: it amplifies the existing pulse window without occupying the receptor on a multi-day clock.

Whenever you see the CJC + Ipa pairing discussed responsibly, it’s the no-DAC version of CJC. The DAC variant exists, has its uses, and is much closer in behavior to low-dose HGH than to a peptide amplifier of the natural axis. The argument for the no-DAC pairing is the preservation of pulsatility itself.

Evidence: where it’s strong, where it stops

Honest version: there is no published randomized controlled trial of CJC-1295 (no DAC) + Ipamorelin in healthy adults. None. The community story for this pairing is built on three pillars:

One. The 2006 Teichman JCEM Phase 1 study of DAC-CJC-1295 documents the PK behavior of the GHRH-analog molecule and confirms that it does what it’s designed to do at the GHRH receptor in humans ¹. The no-DAC version is inferred from the same pharmacology with the half-life modifier stripped.

Two. The 1998 Raun paper in European Journal of Endocrinology is the foundational ipamorelin selectivity study. In rats and swine, ipamorelin produced GH release comparable to the older GHRP-6 but without the prolactin, cortisol, ACTH, LH, FSH, or TSH side activity those older compounds carry ². This is preclinical data, but the selectivity claim is what made ipamorelin the “clean” ghrelin mimetic of choice for human use.

Three. Tesamorelin — the only FDA-approved GHRH analog and the closest pharmacological cousin to CJC-1295 — has Phase 3 regulatory-grade evidence. The pooled analysis of two Phase 3 RCTs in HIV-associated lipodystrophy (n = 806) showed a 15–18% reduction in visceral adipose tissue over 26–52 weeks with IGF-1 rising about 108 ng/mL on average ³. That’s the best regulatory evidence we have for what a GHRH-analog leg of this kind of stack can do clinically. CJC-1295 is the off-label cousin of that drug.

Past those three pillars, almost everything else is either inference from adjacent molecules, animal data, or open-label clinic observation. The mechanism is sound. The receptor-level argument for the synergy is well-grounded. But the depth that readers usually want — how much, in whom, on what cycle, with what timing — is not in the RCT literature. It’s in private clinical practice and informed self-experimentation. We’ll say that directly. We won’t pretend otherwise.

The female axis — what most write-ups miss

Most peptide write-ups treat “women” as a footnote. That’s a mistake here, because the female GH axis isn’t a smaller version of the male one. It’s shaped differently by estrogen route, cycle phase, and the prolactin axis — all of which interact with this specific stack.

The single most important argument for choosing ipamorelin over older ghrelin mimetics (GHRP-6, GHRP-2, hexarelin) for women is prolactin selectivity. Raun’s 1998 data documented that ipamorelin did not raise prolactin in swine even at doses far above the GH-releasing threshold — whereas GHRP-6 and GHRP-2 both elevated prolactin reliably ². For women with cycle irregularity, history of galactorrhea, or a family pattern of prolactinoma screening, that selectivity argument isn’t academic.

The second piece most writeups miss: estrogen route changes the GH–IGF-1 relationship. Estrogen amplifies the GH pulse at the pituitary, but at the liver, oral estrogen suppresses hepatic IGF-1 generation. The practical effect is that women on oral estrogen (oral hormone therapy or oral contraceptive pills) tend to have lower IGF-1 response to the same GH stimulus than men or women on transdermal estrogen. Baseline labs read very differently across these populations.

Cycle phase matters too. The follicular phase — especially the mid-to-late follicular window, where estrogen is climbing toward ovulation — tends to be the most receptive phase for any GH-amplifying signal. The luteal phase carries higher cortisol reactivity and progesterone-driven water retention, which can compound the mild edema some users notice on GH-active peptides. We don’t tabulate the cycle-phase math here. The Manual does — that’s the appropriate depth level for the per-population work.

Risks worth taking seriously

Four risks deserve attention with this pairing. None of them are speculative; all are well-documented in the GH-replacement literature broadly.

Water retention and mild edema. This is a direct GH effect on renal sodium handling and soft tissue. It’s the single most common subjective complaint. Hands feel puffy in the morning, ring sits tighter, sometimes mild ankle swelling. The tesamorelin Phase 3 program documented peripheral edema and arthralgia as recognized class effects ³. If it’s significant, it’s a signal to lower exposure or stop.

Carpal-tunnel-type symptoms. Same fluid-shift mechanism, different location. Hand numbness, paresthesia, wrist-tingle waking from sleep. Reported across the GH-active class. Resolves on discontinuation. Not subtle; pay attention if it appears.

Insulin sensitivity decline. GH is counter-regulatory to insulin. Acutely, it lowers insulin sensitivity and can raise fasting glucose. The tesamorelin program did not see clinically meaningful glucose changes at the studied doses over a year ³, but at the higher exposures community protocols sometimes use, this is the most important lab to track. Baseline fasting glucose, fasting insulin, HbA1c, and a ninety-day recheck are the floor.

The cancer-mitogen conversation. Honestly, this is the section where most peptide articles either hand-wave or catastrophize. We’ll do neither.

IGF-1 is a mitogen. The epidemiology of endogenous IGF-1 and cancer is biphasic and tissue-specific — protective for some endpoints (cerebrovascular aging, frailty), permissively associated with others (some cancers). The Bartke & Darcy 2017 review lays out the “opposite associations across diseases” framing clearly ⁵. Meta-analyses of IGF-1 gene polymorphisms (rs35767 and others) show modest but real associations with overall cancer risk ¹¹. The biological plausibility of the link is real.

What follows from that:

• Pre-existing or active malignancy is a hard contraindication.
• A personal or strong family history of breast, prostate, colorectal, or thyroid cancer makes age-appropriate screening non-optional, not optional, while on or after these compounds.
• The latency uncertainty is real. Long-term human RCT data on healthy adults using GHRH-analog plus ghrelin-mimetic stacks for years doesn’t exist. The right response to that gap is aggressive screening, not abstinence-or-permission framing.

That’s an editorial position, not a clinical one. The clinical position is: this is exactly the type of decision that belongs with a clinician who knows your history, not a peptide article.

Why peptides aren’t “diet HGH”

This is the editorial centerpiece. It’s also the thing the cheapest version of this category gets backwards.

Exogenous human growth hormone (HGH) replaces the pulse with a tonic flood. Most users dose nightly, GH stays elevated for hours, IGF-1 climbs toward a new baseline, and the pituitary’s own pulsatile output downregulates because the brain reads the external GH as adequate signal. That’s the “replacement” model. It works for what it does. It also bypasses the somatostatin feedback loop — the brake the body uses to decide when to stop. There is no off switch except dose changes.

The GHRH-analog plus ghrelin-mimetic pairing does the opposite. It amplifies the existing pulse, which means the somatostatin brake stays in the loop. Each pulse still self-terminates the way the body is designed to terminate it. Receptor occupation is hours, not days. Endogenous production isn’t suppressed; if the pituitary “stops cooperating” for any reason, the signal stops too. That is — not metaphorically — a safety mechanism.

This is the preservation-not-replacement argument, and it’s the editorial frame the rest of the site runs on. Peptides preserve the feedback. HGH bypasses it. The peptide route is also dramatically cheaper, doesn’t suppress endogenous output, and stops when the pituitary stops. For age-related GH decline, that’s a meaningfully different risk profile.

The post-GLP-1 cleanup conversation

The newest reason readers find this article is GLP-1 lean-mass loss, and it’s the angle worth being precise about.

The 2026 cardiology and clinical-nutrition literature is now explicit about the cost. Up to forty percent of weight lost on GLP-1 receptor agonists is lean mass ⁷. Khan and colleagues in the European Heart Journal call for a “paradigm shift … from total weight loss toward high-quality weight loss that preserves or enhances muscle mass” ⁸. Quilliot, writing in Clinical Nutrition ESPEN, goes further — framing inadequately supervised GLP-1 use as potentially iatrogenic, driving sarcopenic obesity over years ⁹. The visible signal is the loss of facial volume, where subcutaneous fat, muscle bed, and collagen all retreat together.

Where GH-axis support fits, mechanistically: GH and IGF-1 are the body’s primary lean-mass-preservation signal. During caloric deficit, GH stimulation shifts substrate utilization toward fat oxidation and helps preserve nitrogen balance. A 2009 rat study found ipamorelin attenuated prednisolone-induced nitrogen wasting and preserved organ nitrogen content ⁶. That’s mechanism, not human evidence in this population.

Where it doesn’t fit, honestly: there is no published randomized trial of CJC + Ipa for post-GLP-1 lean-mass recovery. Anyone telling you otherwise is selling. The first-line steps the cardiology literature actually endorses are protein intake and resistance training. Layering a GH-axis peptide on top is a reasonable mechanistic hypothesis for the right person at the right phase. It is not a validated protocol.

The phase that makes the most sense is also the one most often rushed: after the GLP-1 taper, not during. During the deficit, anabolic signaling has less to land on. As the caloric environment normalizes and resistance training takes hold, a GH-axis support layer has a window where the mechanism can do meaningful work. The full 12-week post-cycle-off framework maps that sequencing in detail. The Manual goes deeper still.

Grey areas: regulation, vendors, WADA

Three things worth being explicit about.

The 503A compounding picture is unsettled. In September 2024, the FDA removed CJC-1295, ipamorelin acetate, AOD-9604, thymosin alpha-1, and Selank from Category 2 of the interim 503A bulk drug substances list. The Pharmacy Compounding Advisory Committee then recommended against adding them to Category 1 in late 2024. Net result: legitimate U.S. compounding pharmacy access for these molecules sits in regulatory limbo. That doesn’t make them legal to obtain through other channels; it just describes the gap that the research-chemical market fills.

The research-chemical channel has real structural problems. No FDA oversight of identity, purity, dose accuracy, endotoxin load, or sterility. Independent reagent-lab analyses continue to find underdosed and contaminated material across the category. A clean Certificate of Analysis ought to include HPLC purity, mass spec confirming molecular weight, an endotoxin (LAL) result, and a third-party lab signature rather than a vendor-internal one. Lyophilized peptide that arrives wet, warm, or with the wrong fill volume should be treated as suspect. We don’t name vendors here; the verification framework is the right depth for the Manual.

WADA bans this pairing at all times. Both CJC-1295 and ipamorelin appear by name on the 2025 WADA Prohibited List, Section S2 (peptide hormones, growth factors, related substances and mimetics) ¹². Prohibited in and out of competition for any tested athlete. Analytical methods to detect them exist and continue to improve. If you compete under any anti-doping authority, this stack is non-negotiable — not as a value judgment, as a fact.

What we still don’t know

The unknowns are worth listing because they bound what anyone — clinic, vendor, peptide influencer — can honestly claim.

• No randomized controlled trial of CJC-1295 (no DAC) + Ipamorelin in healthy adults exists.
• No long-term safety data — more than one year of continuous or cycled use in healthy adults — exists in controlled form for either compound, individually or together.
• No direct cancer-incidence data for chronic GH-secretagogue exposure in healthy adults exists. The mitogen-risk story is mechanistic and epidemiology-by-analogy, not trial-derived.
• No head-to-head human trial comparing this peptide pairing to low-dose HGH exists. The “preservation vs. replacement” framing is a receptor-level argument and a longevity-axis inference, not a trial result.
• Female-specific human trial data across this class is thin. Mechanism-based reasoning from estrogen-GH-axis literature is the strongest footing currently available.

That list isn’t a reason not to take the compounds seriously. It’s a reason to take them seriously the right way — with a clinician, with labs, with screening, and with the understanding that “a lot of people use this” is not the same thing as “this has been studied properly in people.” Most peptides in this category exist in that gap.

References

1. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. DOI.
2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. DOI.
3. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials. J Clin Endocrinol Metab. 2010. DOI.
4. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. DOI.
5. Bartke A, Darcy J. GH and ageing: pitfalls and new insights. Best Pract Res Clin Endocrinol Metab. 2017. DOI.
6. Aagaard NK et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats. Growth Horm IGF Res. 2009. DOI.
7. Alexander SE, Howden EJ. Metabolic rebound and weight cycling following incretin mimetic drug withdrawal: a cause for concern? Curr Opin Clin Nutr Metab Care. 2026. DOI.
8. Khan MS et al. Fat, muscle, and anti-obesity medications in cardiovascular disease prevention. Eur Heart J. 2026. DOI.
9. Quilliot D. Turning obesity into an iatrogenic disease? Clin Nutr ESPEN. 2026. DOI.
10. Bickel MA et al. Cell non-autonomous regulation of cerebrovascular aging processes by the somatotropic axis. Front Endocrinol. 2023. DOI.
11. Qin L et al. Association between insulin-like growth factor 1 gene rs35767 polymorphisms and cancer risk: a meta-analysis. Medicine (Baltimore). 2019. DOI.
12. World Anti-Doping Agency. 2025 Prohibited List, Section S2 (peptide hormones, growth factors and mimetics). WADA.